Go Pro
NASDAQ:TRAX

First Tracks Biotherapeutics Q2 2026 Earnings Report

$46.13 -0.62 (-1.33%)
As of 04:00 PM Eastern

First Tracks Biotherapeutics EPS Results

Actual EPS
-$0.95
Consensus EPS
-$0.74
Beat/Miss
Missed by -$0.21
One Year Ago EPS
N/A

First Tracks Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

First Tracks Biotherapeutics Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
4:00PM ET

First Tracks Biotherapeutics Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
First Tracks Biotherapeutics Inc
See More First Tracks Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like First Tracks Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on First Tracks Biotherapeutics and other key companies, straight to your email.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics (NASDAQ:TRAX) is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

View First Tracks Biotherapeutics Profile